Press Releases |News

11/04/2022

Cardiology

Tempus Announces Six Abstracts Accepted for Presentation at the American Heart Association Scientific Sessions 2022

Tempus, a leader in artificial intelligence and precision medicine, today announced that six abstracts, resulting from its strategic partnership with Geisinger, were accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2022, which convenes in Chicago, Illinois from November 5-7, 2022. This is the fourth year that Tempus has presented w...

11/03/2022

Tempus Launches First Cardiology Prospective Study for its AI-Enabled Predictive Tests

In collaboration with iRhythm, Tempus is studying its predictive, AI-enabled algorithmic tests via a network of researchers to determine the impact of detecting patients at increased risk of developing cardiovascular disease Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of a multi-center study titled, ...

05/25/2022

Tempus and Geisinger Find ECG-Based AI Model Can Predict Undiagnosed Structural Heart Disease

Published in Circulation, the rECHOmmend study expands on AI-focused research to improve patient outcomes in cardiology A team of clinicians and scientists from Tempus and Geisinger have found that a new artificial intelligence model can accurately identify patients at increased risk of undiagnosed structural heart disease....

03/05/2021

Researchers Find AI Can Predict New Atrial Fibrillation, Stroke Risk

A team of scientists from Geisinger and Tempus have found that artificial intelligence can predict risk of new atrial fibrillation (AF) and AF-related stroke. Atrial fibrillation is the most common cardiac arrhythmia and is associated with numerous health risks, including stroke and death. The study, published in Circulation, used el...

12/10/2020

Cardiology

Tempus Announces $200 Million Series G-2 Financing

Tempus, a leader in artificial intelligence and precision medicine, today announced an additional $200 million financing at a post-money valuation of $8.1 billion dollars, and an additional $250 million of convertible debt. The investors include Baillie Gifford, Franklin Templeton, Google, Novo Holdings, and funds and accounts managed by T. Rowe Price....

03/13/2020

Cardiology

Tempus Announces $100 Million in Series G Financing

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced an additional $100 million financing at a post-money valuation of $5 billion dollars. The investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, and funds and accounts managed by T. Rowe Price. ...

01/20/2020

Tempus Unveils AI-Enabled Smart Tests Across Disease Types

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, unveils its AI-enabled laboratory test (smart test) platform. Through its technology, laboratory tests are now able to be embedded with real-world evidence that deliver real-time, actionable insights to physicians, providing critical information...

09/17/2019

Cardiology

Geisinger and Tempus Announce Collaboration to Develop Cardiology Diagnostic and Prognostic Tools Using Artificial Intelligence

Geisinger announced today a new multi-year partnership with Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The collaboration aims to use the power of machine learning and artificial intelligence to build new precision medicine tools for cardiology that will enable...

08/22/2019

Tempus Expands Leadership Team with the Appointment of Joel Dudley, PhD, as Senior Vice President of Research

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announces the appointment of Joel Dudley, PhD, as its Senior Vice President of Research. In his role, Dr. Dudley is responsible for leading Tempus’s research and development efforts...

01/17/2017

Tempus And University Hospitals Seidman Cancer Center announce joint effort to customize treatment for cancer patients

Tempus, a technology company focused on helping doctors personalize cancer care, and University Hospitals Seidman Cancer Center have joined together to improve research and healthcare by making genomic data, advanced molecular analysis and clinical decision support tools available to the hospital's researchers, physicians and healthcare providers.As part...

NEWS

Press Releases

Media Coverage

Additional Partnerships

Blog